GRN — Progranulin

Introduction

Grn — Progranulin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

GRN (Progranulin) is a gene located on chromosome 17q21.31 that encodes the secreted glycoprotein progranulin (PGRN), also known as granulins or epithelins. Progranulin is a highly conserved, multifunctional growth factor that plays critical roles in development, wound healing, inflammation, and neuronal survival^[1]. Mutations in GRN are a major genetic cause of [Frontotemporal Dementia/diseases) (FTD), accounting for approximately 5-10% of all FTD cases and up to 20% of familial FTD^[2]. The gene is catalogued as NCBI Gene ID 2896 and OMIM 138945.

The protein encoded by GRN is [Progranulin/proteins). See the protein page for detailed structural and functional information.

Function

Progranulin Biology

The GRN gene encodes a 593-amino acid precursor protein (progranulin) that contains 7.5 tandem repeats of a highly conserved 12-cysteine granulin domain^[1]. Each granulin domain is approximately 90 amino acids with 12 conserved cysteine residues forming 6 disulfide bonds, creating a compact, stable structure^[3]. Progranulin is secreted as a full-length protein and can be cleaved by extracellular proteases (including neutrophil elastase, proteinase 3, and MMP-9) into smaller, functional granulin peptides (GRN A-G)^[4].

Normal Physiological Functions

• Neuronal survival: Progranulin supports neuronal viability through activation of AKT and ERK signaling pathways^[5]

• Microglial function: Regulates microglial activation and neuroinflammation^[6]

• Synaptic plasticity: Involved in synaptic formation and maintenance^[7]

• Protein homeostasis: Regulates lysosomal function and autophagy^[8]

• Wound healing: Promotes cell proliferation and migration

Brain Expression

Progranulin is expressed in multiple brain regions:

• Cerebral cortex (highest expression in layer 5 pyramidal neurons)

• Hippocampus (CA1-CA3 regions, dentate gyrus)

• Microglia (activated states)

• Substantia nigra (dopaminergic neurons)

• Cerebellum (Purkinje cells)

Expression data is available from the Allen Human Brain Atlas.

Allen Brain Atlas Data

Gene Expression

Progranulin (GRN) shows broad expression in the brain:

• Microglia - High expression, especially in activated states

• Neurons - Moderate expression in various neuronal populations

• Astrocytes - Variable expression

• Cerebellum - Expression in Purkinje cells

• Substantia nigra - Expression in dopaminergic neurons

Single-Cell Expression

Single-cell RNA-seq data from the Allen Brain Atlas shows:

• Microglia - High expression, increases with activation

• Macrophages - High expression in border-associated populations

• Neurons - Variable expression across types

• Astrocytes - Moderate expression

Brain Region Expression Levels

External Resources

• Allen Human Brain Atlas - GRN

• Allen Mouse Brain Atlas - GRN

• Allen Cell Type Atlas - GRN

Molecular Mechanism in Neurodegeneration

Haploinsufficiency Model

The majority of disease-causing GRN mutations result in loss-of-function, leading to ~50% reduction in progranulin protein levels (haploinsufficiency)^[2]. This haploinsufficiency model is supported by:

• Frameshift, nonsense, and splice-site mutations that create premature termination codons

• Null alleles identified in affected individuals

• Reduced progranulin levels in cerebrospinal fluid (CSF) of mutation carriers^[9]

TDP-43 Pathology

GRN mutations cause a distinctive neuropathological signature characterized by:

• TDP-43 proteinopathy: Accumulation of hyperphosphorylated, ubiquitinated TDP-43 inclusions in the cytoplasm of neurons^[10]

• Neuronal loss: Particularly in frontal and temporal cortices

• Gliosis: Reactive astrocytes and microglia

The link between progranulin deficiency and TDP-43 pathology involves:

1. Impaired lysosomal function: Progranulin localizes to lysosomes and regulates cathepsin activity^[8]

2. Autophagy disruption: Reduced progranulin leads to impaired autophagic flux

3. TDP-43 mislocalization: Loss of progranulin disrupts nuclear-cytoplasmic TDP-43 homeostasis

4. Endoplasmic reticulum stress: Progranulin deficiency induces ER stress response

Neuroinflammation

Progranulin has immunomodulatory functions:

• Microglial activation is dysregulated in GRN mutation carriers

• Increased pro-inflammatory cytokines (IL-1β, TNF-α) in GRN-deficient brains

• Altered complement system activation

Disease Associations

Primary Diseases

1. Frontotemporal Dementia (FTD)

   • Most common manifestation of GRN mutations

   • Typically presents as behavioral variant FTD (bvFTD) or primary progressive aphasia (PPA)

   • Mean age of onset: 58-65 years

   • Disease duration: 6-12 years

2. Neuronal Ceroid Lipofuscinosis (NCL)

   • Rare homozygous GRN mutations cause atypical NCL

   • Characterized by lipofuscin accumulation

   • Childhood onset with progressive neurodegeneration

Secondary Associations

3. Alzheimer’s Disease

   • GRN polymorphisms influence AD risk

   • Progranulin levels altered in AD brains

   • May interact with amyloid and tau pathology

4. Parkinson’s Disease

   • Some GRN variants associated with PD risk

   • TDP-43 pathology observed in some PD cases

5. Amyotrophic Lateral Sclerosis (ALS)

   • Overlap between FTD and ALS

   • Some GRN mutations in ALS-FTD spectrum

Key Mutations

Therapeutic Approaches

Progranulin Restoration

1. Gene therapy: AAV-mediated GRN delivery to increase progranulin expression^[11]

2. Protein replacement: Recombinant progranulin administration

3. Small molecules: Drugs that upregulate GRN expression

Protease Inhibition

• Tetracycline antibiotics: Minocycline inhibits proteases that cleave progranulin

• Synthetic protease inhibitors: Designed to prevent granulin generation

Symptomatic Treatments

• Behavioral interventions for FTD symptoms

• SSRIs for depression and anxiety

• Occupational therapy for functional decline

Key Publications

1. Null progranulin mutations cause frontotemporal lobar degeneration with TDP-43 pathology. Nature, 2006. PMID: 16645517

2. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 2006. PMID: 16641942

3. Progranulin deficiency promotes circuit-specific synaptic pruning by astrocytes via the complement C1q receptor. Science, 2018. PMID: 29954983

4. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. Journal of Neuroscience Research, 2019. PMID: 30734333

5. Progranulin deficiency leads to age-dependent deficits in cognitive function. Neurobiology of Aging, 2020. PMID: 31980241

External Links

• NCBI Gene: https://www.ncbi.nlm.nih.gov/gene/2896

• Ensembl: https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000030582

• OMIM: https://omim.org/entry/138945

• UniProt: https://www.uniprot.org/uniprot/P28799

• Allen Human Brain Atlas: GRN expression

• AlzGene: GRN polymorphism associations

See Also

• Genes Index

• Proteins Index

  • [Progranulin Protein/proteins)

  • [TDP-43 Protein[/[proteins-tdp-43

• Diseases Index

  • Frontotemporal Dementia/diseases)

  • Parkinson’s Disease/diseases)

• Mechanisms Index

  • [TDP-43 Proteinopathy/mechanisms)

Background

The study of Grn — Progranulin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Pathway Diagram

flowchart TD
    A["GRN Gene<br/>17q21.31 -> BProgranulin Protein<br/>Secreted growth factor"]
    B  -->  C["Normal Function<br/>Cell Growth and Survival"]
    C  -->  D["Neurotrophic Signaling"]
    D  -->  E["Neuronal Survival"]
    E  -->  F["Cognitive Function"]
    
    G["GRN Mutations<br/>Loss of Function -> HReduced Progranulin"]
    H  -->  I["Microglial Activation"]
    I  -->  J["Excessive Phagocytosis"]
    J  -->  K["Synaptic Loss"]
    
    H  -->  L["TDP-43 Pathology"]
    L  -->  M["Cytoplasmic Inclusions"]
    M  -->  N["Neuronal Dysfunction"]
    
    H  -->  O["Inflammation"]
    O  -->  P["Neuroinflammation"]
    P  -->  Q["Frontotemporal Dementia<br/>GRN-FTD"]
    
    R["Reduced Lysosomal<br/>Function -> H"]
    
    style A fill:#1a0a1f,stroke:#333
    style Q fill:#3b1114,stroke:#333

Disease Mechanism Summary

Brain Atlas Resources

• Allen Human Brain Atlas search: GRN — Progranulin

• Allen Mouse Brain Atlas search: GRN — Progranulin

• Allen Brain Map portal search: GRN — Progranulin

• BrainSpan developmental transcriptome search: GRN — Progranulin

^{8Frontotemporal Dementia2024 · PubMed · PMID 39620838Open reference}: Frontotemporal Dementia. PMID: 39620838. PubMed. 2024.

^{9Frontotemporal dementia: from genetics to therapeutic approaches2024 · PubMed · PMID 38687620Open reference}: Frontotemporal dementia: from genetics to therapeutic approaches. PMID: 38687620. PubMed. 2024.

^{10Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results2024 · PubMed · PMID 38745011Open reference}: Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results. PMID: 38745011. PubMed. 2024.

^{2Microglial activation in progranulin-deficient brains2019 · Acta Neuropathologica Communications · DOI 10.1186/s40478-019-0740-4Open reference}0: Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results. PMID: 38623902. PubMed. 2024.

^{2Microglial activation in progranulin-deficient brains2019 · Acta Neuropathologica Communications · DOI 10.1186/s40478-019-0740-4Open reference}1: Phase 1 study of latozinemab in progranulin-associated frontotemporal dementia. PMID: 38356474. PubMed. 2024.

^{2Microglial activation in progranulin-deficient brains2019 · Acta Neuropathologica Communications · DOI 10.1186/s40478-019-0740-4Open reference}2: A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factors. PMID: 38539243. PubMed. 2024.

^{2Microglial activation in progranulin-deficient brains2019 · Acta Neuropathologica Communications · DOI 10.1186/s40478-019-0740-4Open reference}3: Granulins rescue inflammation, lysosome dysfunction, lipofuscin, and neuropathology in a mouse model of progranulin deficiency. PMID: 39565694. PubMed. 2024.

^{2Microglial activation in progranulin-deficient brains2019 · Acta Neuropathologica Communications · DOI 10.1186/s40478-019-0740-4Open reference}4: Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review. PMID: 39519389. PubMed. 2024.

^{2Microglial activation in progranulin-deficient brains2019 · Acta Neuropathologica Communications · DOI 10.1186/s40478-019-0740-4Open reference}5: Targeting complement C3a receptor resolves mitochondrial hyperfusion and subretinal microglial activation in progranulin-deficient frontotemporal dementia. PMID: 38854134. PubMed. 2024.

^{2Microglial activation in progranulin-deficient brains2019 · Acta Neuropathologica Communications · DOI 10.1186/s40478-019-0740-4Open reference}6: An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation. PMID: 39185427. PubMed. 2024.

Structure

AlphaFold DB provides a full-length predicted structure for GRN (UniProt P28799, model v6) with mean pLDDT 77.0. View the model at AlphaFold DB or download the PDB file.

Domain and region confidence from per-residue pLDDT:

• Residues 1-593 (full-length protein): mean pLDDT 77.0 (confident).

Overall confidence distribution: 125 residues (21%) very high, 342 residues (58%) confident, 40 residues (7%) low, 86 residues (15%) very low. Low or very-low pLDDT segments should be interpreted as flexible or disordered regions rather than resolved binding pockets.

UniProt function annotation: Secreted protein that acts as a key regulator of lysosomal function and as a growth factor involved in inflammation, wound healing and cell proliferation (PubMed:12526812, PubMed:18378771, PubMed:28073925, PubMed:28453791, PubMed:28541286). Regulates protein trafficking to lysosomes, and also the activity of lysosomal enzymes (PubMed:28453791. Subcellular localization: Secreted, Lysosome. Curated disease associations include: Frontotemporal dementia 2; Ceroid lipofuscinosis, neuronal, 11.